NATIONAL ASSSOCIATIONS COUNCIL

Priorities

The next few years are going to be decisive for the European sector. In 2025, the group will focus on key legislative and non-legislative priorities to drive and scale biotech innovation across Europe.

These include supporting the development of an ambitious, cross-sectoral Biotech Act. Building on the EU's Startup and Scaleup Strategy expected earlier in the year.

To help deliver these strategies, the group will put forward policy recommendations on investment and financing. It will advocate for a Multiannual Financial Framework that reflects the sector's potential and enhances its global competitiveness. As well as improved access to private funding through European capital markets.

The group will also work to expand Europe's Bioeconomy by bridging national strategies and connecting ecosystems across Eastern and Western Europe.

To attract investment, it will continue to prioritize intellectual property protection and biopatents. Including for plant innovations developed through new genomic techniques.

The group will also push for stronger support for quality jobs, skills, and education, ensuring that Europe's industry has the talent, expertise, and capacity it needs to grow.

In healthcare, it will continue its work on access to critical medicines and contribute to the revision of the General Pharmaceutical Legislation. Aligning it with the EU Life Sciences Strategy to make sure the industry is able to deliver breakthrough therapies to patients across Europe.